Undoubtedly there exists a need to improve the care of and outcomes for children who are suffering from asthma. This blog ...

Kinaset Therapeutics, a clinical-stage biopharmaceutical company developing inhaled therapeutics to treat serious respiratory diseases, today announced that the United States Food and Drug ...

What is the best step-up treatment for people whose asthma is not controlled on a combination inhaler of ICS plus formoterol used as needed? For a short explanation of why the committee made this ...

What is the clinical and cost-effectiveness of regular 'fixed-dose' inhaled corticosteroid (ICS) regimens (using SABA [short-acting beta2 agonist] as a reliever) compared with 'as-needed' strategies ...

COPD: Chronic obstructive pulmonary disease; EIB: Exercise-induced bronchoconstriction; IβA: Inhaled β 2-agonist; ICS: Inhaled corticosteroid. Globally, the prevalence of asthma continues to ...

Operator Hello, and welcome to the fourth quarter and full year 2024 Teva Pharmaceutical Industries earnings conference call.

MACE incidence in patients with COPD initiating triple therapy was 11.3/100/year vs 8.7/100/year in patients using LABA-ICS. In patients with chronic obstructive pulmonary disease (COPD), the first ...

EMA accepts for review GSK’s MAA for depemokimab for use in asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 09:00 Hrs [IST] GSK plc announced ...

Although inhaled steroids are the treatment of choice ... with uncontrolled persistent asthma that doesn't respond to ICS therapy, but only if adding a long-acting beta-agonist is not appropriate ...

Venture capital group Abingworth is reportedly trying to raise up to $1.5 billion in investment funding to support biopharma companies' clinical development programmes in return for royalties on ...